Abstract
The serial interval of an infectious disease, commonly interpreted as the time between onset of symptoms in sequentially infected individuals within a chain of transmission, is a key epidemiological quantity involved in estimating the reproduction number. The serial interval is closely related to other key quantities, including the incubation period, the generation interval (the time between sequential infections) and time delays between infection and the observations associated with monitoring an outbreak such as confirmed cases, hospital admissions and deaths. Estimates of these quantities are often based on small data sets from early contact tracing and are subject to considerable uncertainty, which is especially true for early COVID-19 data. In this paper we estimate these key quantities in the context of COVID-19 for the UK, including a meta-analysis of early estimates of the serial interval. We estimate distributions for the serial interval with a mean 5.6 (95% CrI 5.1–6.2) and SD 4.2 (95% CrI 3.9–4.6) days (empirical distribution), the generation interval with a mean 4.8 (95% CrI 4.3–5.41) and SD 1.7 (95% CrI 1.0–2.6) days (fitted gamma distribution), and the incubation period with a mean 5.5 (95% CrI 5.1–5.8) and SD 4.9 (95% CrI 4.5–5.3) days (fitted log normal distribution). We quantify the impact of the uncertainty surrounding the serial interval, generation interval, incubation period and time delays, on the subsequent estimation of the reproduction number, when pragmatic and more formal approaches are taken. These estimates place empirical bounds on the estimates of most relevant model parameters and are expected to contribute to modelling COVID-19 transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding: RC and KTA gratefully acknowledges the financial support of the EPSRC via grant EP/N014391/1 and NHS England, Global Digital Exemplar programme. LD and KTA gratefully acknowledges the financial support of The Alan Turing Institute under the EPSRC grant EP/N510129/1. LL acknowledges the financial support of the EPSRC via Early Career Fellowship EP/P01660X/1. LD and EBP are supported by Medical Research Council (MRC) (MC/PC/19067). EBP was partly supported by the NIHR Health Protection Research Unit in Behavioural Science and Evaluation at University of Bristol, in partnership with Public Health England (PHE).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
None required
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All code is available on GitHub. Some source data is restricted as comes from potentially identifiable sources but aggregate data can be provided by the authors.
https://github.com/terminological/uk-covid-datatools/vignettes/serial-interval
